Citadel Advisors’s Evoke Pharma EVOK Stock Holding History

Citadel Advisors’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,542	Closed	-$33K	–	13103
2025 Q2	$33K	Sell	12,542 -12,261	-49%	-$35.3K	﹤0.01%	11950
2025 Q1	$68.2K	Buy	+24,803	New	+$105K	﹤0.01%	11950
2024 Q3	–	Sell	-993	Closed	-$6.3K	–	14482
2024 Q2	$6.3K	Buy	+993	New	+$5.98K	﹤0.01%	13341
2022 Q1	–	Sell	-185	Closed	-$15K	–	13854
2021 Q4	$15K	Sell	185 -91	-33%	-$12.7K	﹤0.01%	13624
2021 Q3	$52K	Buy	276 +4	+1%	+$674	﹤0.01%	13350
2021 Q2	$54K	Buy	+272	New	+$58.2K	﹤0.01%	13305
2020 Q4	–	Sell	-159	Closed	-$81.9K	–	11067
2020 Q3	$108K	Buy	+159	New	+$101K	﹤0.01%	9232
2020 Q2	–	Sell	-185	Closed	-$31K	–	9960
2020 Q1	$31K	Buy	+185	New	+$35.5K	﹤0.01%	9186
2019 Q3	–	Sell	-410	Closed	-$37K	–	9309
2019 Q2	$37K	Buy	+410	New	+$40.6K	﹤0.01%	8814
2018 Q1	–	Sell	-81	Closed	-$26K	–	8399
2017 Q4	$26K	Buy	+81	New	+$33.6K	﹤0.01%	7788
2017 Q1	–	Sell	-116	Closed	-$34K	–	7588
2016 Q4	$34K	Buy	+116	New	+$30K	﹤0.01%	6959

Other funds holding EVOK

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's EVOK Position: Q3 2025 in Review

Citadel Advisors sold out of Evoke Pharma (EVOK) in Q3 2025, closing a stake of 12,542 shares — an estimated $33K sold.

Citadel Advisors first reported a position in EVOK in Q4 2016 and held it in 11 quarters. The position peaked at $108K in Q3 2020. 15 funds tracked by Wall St. Rank hold EVOK as of Q3 2025.

Citadel Advisors reported no remaining Evoke Pharma position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 12,542 Evoke Pharma shares in Q3 2025, an estimated $33K.
Citadel Advisors first reported a position in Evoke Pharma in Q4 2016 and held it in 11 quarters.
Citadel Advisors's Evoke Pharma position peaked at $108K in Q3 2020.
15 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.